The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2023 | LUPER: lurbinectedin in combination with pembrolizumab in relapsed SCLC
Antonio Calles Blanco, MD, Gregorio Maranon General University Hospital, Madrid, Spain, discusses results from the LUPER study (NCT04358237), which investigated the efficacy and safety of lurbinectedin in combination with pembrolizumab as a second-line treatment for relapsed small cell lung cancer (SCLC). The preliminary overall response rate was 46.4%, with a median duration of response of 11.4 months. The combination demonstrated effectiveness with manageable safety, suggesting its potential as a second-line therapy for SCLC, warranting further investigation. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
